Salmonella bacteriophage targeting salmonella lipopolysaccharide O antigen and application of salmonella bacteriophage

By developing salmonobacterial phage vB_SalM-ps4, which targets salmonobacterial lipopolysaccharide O antigen, the problem of narrow cleavage spectrum of salmonobacterial phage strains is solved, and effective inhibition of a variety of salmonobacterial and E. coli O157:H7 is achieved, and the A stable, efficient and environmentally friendly alternative therapy suitable for livestock and poultry breeding and food processing.

CN119040274AActive Publication Date: 2024-11-29HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411143174.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-29
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The existing cleavage spectrum of salmonella phage strains is narrow, limiting its application in livestock and poultry breeding, and the excessive use of antibiotics leads to increased bacterial resistance, requiring a stable, efficient and environmentally friendly alternative therapy.

Method used

A salmonobacter phage vB_SalM-ps4 targeting the salmonobacter lipopolysaccharide O antigen was developed. This phage has broad spectrum resistance and is able to recognize a variety of salmonobacter and E. coli O157:H7 for the preparation of inhibiting and eliminating salmonobacter Preparation, suitable for livestock and poultry breeding and food processing.

Benefits of technology

Salmonella phage vB_SalM-ps4 is stable within a certain temperature and acid-base range, has high safety and a wide range of application fields. It can effectively inhibit and remove Salmonella biofilm, significantly reduce Salmonella contamination, and is suitable for preventing and treating Salmonella infection. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040274A_ABST
    Figure CN119040274A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of bacteriophages, and particularly relates to a salmonella bacteriophage targeting a salmonella lipopolysaccharide O antigen and application of the salmonella bacteriophage. The salmonella bacteriophage vBSalM-ps4 does not contain virulence genes, is high in safety, good in stability at a certain temperature and within a certain acid-base range, wide in tolerance range, capable of effectively inhibiting and removing a biofilm formed by salmonella, capable of removing and inhibiting various salmonella, wide in lysis spectrum and capable of being used for preparing the salmonella bacteriophage vBSalM-ps4. The feed additive has good prevention and removal effects on salmonella in food and feed infected by salmonella; meanwhile, the salmonella bacteriophage vBSalM-ps4 can also perform cross-species lysis on escherichia coli O157: H7, and the application field is wide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bacteriophages, and in particular relates to a Salmonella phage targeting Salmonella lipopolysaccharide O antigen and an application thereof. Background Art

[0002] Salmonella is a Gram-negative bacterium and one of the most important zoonotic foodborne pathogens worldwide, which can cause a variety of diseases. According to statistics, more than 2,500 serotypes of Salmonella have been identified, some of which, especially Salmonella Enteritidis and Salmonella Typhimurium, are very likely to cause microbial contamination and lead to human and animal diseases. Salmonella is usually found in the intestines of warm-blooded animals, so it is easy to transfer from the environment to meat during slaughter and processing. Poultry meat and other foods such as fresh vegetables and fruits are media for human contact with Salmonella, and Salmonella infections caused by these routes are warnings that the control and prevention of Salmonella contamination is imminent.

[0003] At present, in the production process of animal husbandry, antibiotics are still the primary treatment for bacterial infections caused by Salmonella. However, it has been proven that due to repeated use and irrational use of antibiotics, pathogenic bacteria are very likely to develop drug resistance, which is posing a threat to global health. Therefore, in order to prevent and treat Salmonella infections, a stable, efficient and environmentally friendly antibiotic alternative therapy is urgently needed.

[0004] Bacteriophage is a virus that can infect bacteria. It has a high degree of host specificity and is the most abundant biological entity on earth. Compared with traditional antibiotics, it can specifically infect target bacteria without affecting the normal microbial environment. It has the characteristics of using bacteria to replicate itself and will not cause harm to animals and humans. After nearly a hundred years of development, bacteriophage has become an environmentally friendly biological control agent for eliminating foodborne pathogens. So far, commercially recognized bacteriophage products have appeared on the market in my country, such as poultry breeding environment bacteriophage improvers, which have been used to improve the poultry breeding environment. However, the current Salmonella phage strains have a narrow lysis spectrum, which greatly limits the application of Salmonella phage strains in livestock and poultry breeding. Summary of the invention

[0005] The object of the present invention is to provide a Salmonella phage targeting Salmonella lipopolysaccharide O antigen and its application. The Salmonella phage can recognize multiple Salmonella, has a wide lysis spectrum, and can cross-species lyse O157 serotype Escherichia coli.

[0006] The invention provides a Salmonella phage vB_SalM-ps4. The preservation number of the Salmonella phage vB_SalM-ps4 is CCTCCNO: M 20241333.

[0007] The present invention provides the use of the Salmonella phage vB_SalM-ps4 described in the above technical solution in one or both of the following two items:

[0008] 1) Preparation of preparations for inhibiting and / or eliminating Salmonella;

[0009] 2) Preparation of preparations for inhibiting and / or eliminating Escherichia coli.

[0010] Preferably, the preparation in 1) comprises a preparation that targets Salmonella polysaccharides and / or removes Salmonella biofilm.

[0011] Preferably, the Escherichia coli comprises serotype O157 Escherichia coli.

[0012] Preferably, the Salmonella includes one or more of Salmonella Enteritidis, Salmonella Pullorum, Salmonella Stanley, Salmonella Chester, Salmonella Infantis and Salmonella Typhimurium.

[0013] Preferably, the preparation comprises one or more of the following four items:

[0014] 1) Drugs for preventing and / or treating diseases caused by Escherichia coli infection;

[0015] 2) Drugs for preventing and / or treating diseases caused by Salmonella infection;

[0016] 3) Food antibacterial agent;

[0017] 4) Disinfectant.

[0018] Preferably, the food comprises food of animal origin.

[0019] The present invention also provides a preparation, which comprises auxiliary materials and the Salmonella phage vB_SalM-ps4 described in the above technical solution.

[0020] Preferably, the auxiliary material includes feed;

[0021] The content of Salmonella phage vB_SalM-ps4 in the preparation is 10 6 PFU / mL~10 9 PFU / mL.

[0022] The present invention also provides the use of the Salmonella phage vB_SalM-ps4 described in the above technical solution or the preparation described in the above technical solution in livestock and poultry breeding and / or livestock and poultry food processing.

[0023] Beneficial effects:

[0024] The invention provides a Salmonella phage vB_SalM-ps4, and the deposit number of the Salmonella phage vB_SalM-ps4 is CCTCCNO: M 20241333. The Salmonella phage vB_SalM-ps4 of the invention does not contain virulence genes, has high safety, good stability within a certain temperature and acid-base range, and a wide tolerance range, can effectively inhibit and remove biofilms formed by Salmonella, and further has a removal and inhibition effect on multiple Salmonella, has a wide lysis spectrum, and has a good prevention and removal effect on Salmonella in food and feed infected by Salmonella; at the same time, the Salmonella phage vB_SalM-ps4 can also cross-species lyse Escherichia coli O157:H7, and has a wide application field.

[0025] Biological deposit information

[0026] Salmonella phage vB_SalM-ps4 was deposited in the China Center for Type Culture Collection on June 21, 2024. The deposit address is: Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the deposit number is: CCTCC NO: M 20241333. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0028] Figure 1 This is a plaque morphology diagram of the Salmonella phage vB_SalM-ps4 after purification using Salmonella enteritidis SE006 as the host bacteria in Example 1;

[0029] Figure 2 The transmission electron microscopic morphology of the Salmonella phage vB_SalM-ps4 in Example 1;

[0030] Figure 3 The genome annotation circle diagram of Salmonella phage vB_SalM-ps4 in Example 2;

[0031] Figure 4 This is a diagram for identifying the targeting receptor of Salmonella phage vB_SalM-ps4 in Example 4;

[0032] Figure 5This is a diagram showing the optimal MOI experimental result of Salmonella phage vB_SalM-ps4 in Example 5;

[0033] Figure 6 The one-step growth curve result diagram of Salmonella phage vB_SalM-ps4 in Example 6;

[0034] Figure 7 This is a graph showing the pH stability results of Salmonella phage vB_SalM-ps4 in Example 7;

[0035] Figure 8 This is a graph showing the thermal stability results of Salmonella phage vB_SalM-ps4 in Example 8;

[0036] Fig. 9 The inhibition of biofilm by Salmonella phage vB_SalM-ps4 in Example 9;

[0037] Fig.10 The clearing effect of Salmonella phage vB_SalM-ps4 on mature biofilm in Example 10;

[0038] Fig.11 Determination of the control of Salmonella contamination in chicken feed by Salmonella phage vB_SalM-ps4 in Example 11;

[0039] Fig.12 This is the inhibitory effect of the Salmonella phage vB_SalM-ps4 in Example 12 on Salmonella in chicken. DETAILED DESCRIPTION

[0040] The invention provides a Salmonella phage vB_SalM-ps4. The preservation number of the Salmonella phage vB_SalM-ps4 is CCTCCNO: M 20241333.

[0041] The Salmonella phage vB_SalM-ps4 of the present invention is separated and screened from urban sewage, and can form transparent plaques on an LB double-layer plate. The head of the Salmonella phage vB_SalM-ps4 is a regular polyhedron structure, and the tail is retractable through transmission electron microscopy. The head diameter is 85±5nm, and the tail length is 90±5nm. It belongs to the family Myoviridae. The Salmonella phage vB_SalM-ps4 of the present invention is stable in activity after being placed in an environment with a pH value of 3 to 11 for 1 hour; the activity is stable under the temperature conditions of 4°C-50°C, and the titer remains basically unchanged. It still maintains good stability at 60°C, and the phage titer can still be maintained at 1×10 7PFU / mL. The genome size of the Salmonella phage vB_SalM-ps4 described in the present invention is 158583bp, and the genome sequence has been submitted to GeneBank with the accession number PP533474; the results of whole genome sequencing show that the Salmonella phage vB_SalM-ps4 does not contain virulence genes and drug resistance genes. It has been verified through experiments that the Salmonella phage vB_SalM-ps4 described in the present invention can lyse a variety of Salmonella including Enteritidis Salmonella, Pullorum Salmonella, Stanley Salmonella, Chester Salmonella, Infants Salmonella and Salmonella Typhimurium with a wide lysis spectrum; at the same time, it can cross-species lyse Escherichia coli O157:H7 and has a wide range of applications.

[0042] Based on the above advantages, the present invention provides the use of the Salmonella phage vB_SalM-ps4 described in the above technical scheme in one or both of the following two items: 1) preparing a preparation for inhibiting and / or eliminating Salmonella; 2) preparing a preparation for inhibiting and / or eliminating Escherichia coli.

[0043] The preparation of the present invention preferably includes a preparation that targets Salmonella polysaccharides and / or removes Salmonella biofilm. The Escherichia coli of the present invention preferably includes Escherichia coli serotype O157; the Salmonella preferably includes one or more of Salmonella Enteritidis, Salmonella Pullorum, Salmonella Stanley, Salmonella Chester, Salmonella Infantis and Salmonella Typhimurium, more preferably Salmonella Enteritidis and / or Salmonella Typhimurium.

[0044] The preparation of the present invention preferably includes one or more of the following four items: 1) drugs for preventing and / or treating diseases caused by Escherichia coli infection; 2) drugs for preventing and / or treating diseases caused by Salmonella infection; 3) food antibacterial agent; 4) disinfectant. The food antibacterial agent of the present invention is preferably used to inhibit or kill Salmonella on the surface of food or in food. The food of the present invention preferably includes animal-derived food, further preferably including but not limited to livestock and poultry meat products, more preferably including but not limited to chicken. The Escherichia coli of the present invention preferably includes Escherichia coli serotype O157; the Salmonella preferably includes one or more of Salmonella enteritidis, Salmonella pullorum, Salmonella Stanley, Salmonella Chester, Salmonella infantis and Salmonella typhimurium, more preferably Salmonella enteritidis and / or Salmonella typhimurium.

[0045] The present invention also provides a preparation, which comprises an auxiliary material and the Salmonella phage vB_SalM-ps4 described in the above technical solution. The auxiliary material of the present invention preferably includes but is not limited to feed, and can be selected according to the type of preparation according to the corresponding standards in the art. For example, when used as a food antibacterial agent, the auxiliary material can be selected from the auxiliary material type commonly used in food antibacterial agents; the content of Salmonella phage vB_SalM-ps4 in the preparation is preferably 10 6 PFU / mL~10 9 PFU / mL, more preferably 10 7 PFU / mL~10 8 PFU / mL.

[0046] The present invention also provides the use of the Salmonella phage vB_SalM-ps4 described in the above technical solution or the preparation described in the above technical solution in livestock and poultry breeding and / or livestock and poultry food processing. The livestock and poultry food described in the present invention preferably includes but is not limited to meat products.

[0047] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0048] Example 1

[0049] Isolation, purification, proliferation and morphological analysis of bacteriophages

[0050] (I) Isolation and purification of bacteriophage

[0051] The collected urban sewage samples were centrifuged at 6000g for 5 min to remove impurities, and the supernatant was filtered with a 0.22μm filter for later use. 2mL of Salmonella enteritidis SE006 in the logarithmic growth phase (Gao D, Ji H, Wang L, Li X, Hu D, Zhao J, Wang S, Tao P, Li X, Qian P. Fitness Trade-Offs in Phage Cocktail-ResistantSalmonella enterica Serovar Enteritidis Results in Increased Antibiotic Susceptibility and Reduced Virulence. Microbiol Spectr. 2022Oct26; 10(5): e0291422. doi: 10.1128 / spectrum.02914-22. Epub 2022Sep 27.PMID:36165776;PMCID:PMC9603643. has been published) suspension was added to 3mL of LB liquid culture medium, mixed with 2mL of filtered sewage, and placed in a shaker for constant temperature enrichment at 37°C for 6h. The enriched mixture was centrifuged at 12000g for 5min, and the supernatant was filtered with a 0.22μm filter. After gradient dilution, 100μL of different gradient dilutions were taken, mixed with 100μL of host bacteria SE006, and added to 5mL of melted LB semi-solid culture medium (containing 0.7% agar), mixed and covered on LB solid agar (containing 1.5% agar). Place in a 37°C constant temperature incubator for constant culture. Select a single transparent plaque and pick it up with a small gun tip and place it in SM buffer to resuspend it to obtain a phage extract. The extract was filtered through a 0.22 μm filter and then the double-layer plate method was used to detect the phage single plaques. The phage single plaques purified at least three times were amplified and cultured, and after the titer was detected, they were stored at 4° C. and named vB_SalM-ps4.

[0052] (II) Phage proliferation

[0053] The purified phage vB_SalM-ps4 extract was added to the Enteritidis Salmonella SE006 cultured to the logarithmic growth phase and incubated at 37°C in a shaker for 4 hours. After the phage was lysed and proliferated from the host bacteria, the lysate was centrifuged at 8000g for 5 minutes, the supernatant was taken and the residual bacteria were filtered through a 0.22μm filter to obtain the proliferated phage extract. The titer was tested and stored at 4°C.

[0054] (III) Observation of phage plaque morphology

[0055] After gradient dilution of the purified phage vB_SalM-ps4, 100 μL of each gradient dilution was taken, mixed with 100 μL of host bacteria SE006, and added to 5 mL of melted LB semi-solid medium. After mixing, the mixture was evenly covered on LB solid agar. After cooling, it was placed in an inverted incubator at 37°C for culture. After 12 hours, the morphology of the plaques was observed. The results are as follows: Figure 1 As shown, the formation of clear circles on the double-layer plate proves that the phage has been successfully isolated and is real.

[0056] (IV) Observation of phage morphology by transmission electron microscopy

[0057] Using the phosphotungstic acid negative staining method, take a drop of purified high-titer phage extract and immerse the copper mesh for 10 minutes, then use filter paper to absorb the residual suspension on the surface, use 2% phosphotungstic acid (PTA, 2% w / v) dye to negatively stain for 2 minutes, then dry naturally, and place the prepared copper mesh under a transmission electron microscope for observation. The results are as follows Figure 2 As shown. After observation under transmission electron microscopy, it was found that the phage belonged to the order Caudovirales and the family Myoviridae in morphological classification.

[0058] Example 2

[0059] Analysis of the genome of bacteriophage vB_SalM-ps4

[0060] The whole genome of phage vB_SalM-ps4 was assembled and the obtained whole genome sequence was submitted to GenBank with the accession number PP533474. The genome was annotated using the RAST online website (http: / / rast.nmpdr.org / ), and then manually verified using the BLST tool of NCBI (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). The CARD online website (https: / / card.mcmaster.ca / analyze / rgi) was used to analyze whether there were antibiotic resistance and virulence genes in the phage genome, and finally the lysogeny-related proteins in the phage genome were detected.

[0061] The results are as follows Figure 3 As shown in the functional annotation diagram of the phage's entire genome, there are no antibiotic resistance and virulence genes in the phage genome, and there are no lysogeny-related proteins, indicating that the phage has no components that can pose a threat to humans and can be used clinically.

[0062] Example 3

[0063] The detection method of the lysis spectrum of bacteriophage vB_SalM-ps4 is as follows:

[0064] The bacteria for determining the lysis spectrum of bacteriophage vB_SalM-ps4 were all from the laboratory. This embodiment uses a double-layer plate method to determine the lysis spectrum of bacteriophage. Take the bacterial strain, add it to LB liquid culture medium and culture it overnight at 37°C, take 100 μL of bacterial solution and add it to 5mL LB melted semi-solid culture medium, mix it and pour it into a double-layer plate. After it cools and solidifies, dilute the bacteriophage vB_SalM-ps4 10 times in a gradient, take 10 μL of phage extracts of different gradients and drip them on the double-layer plate, dry it naturally until it does not flow, and then invert it in a 37°C constant temperature incubator and culture it for 6 to 12 hours, observe the lysis of the test strain by the bacteriophage, and calculate the phage plaque efficiency (EOP) according to formula I.

[0065] EOP = test bacteria phage titer / host bacteria phage titer (Formula I).

[0066] The test results are shown in Table 1. The phage can lyse multiple serotypes of Salmonella and can lyse Escherichia coli O157:H7. It has cross-species lysis ability and a relatively broad spectrum of activity against Salmonella.

[0067] Table 1 Phage lysis spectrum

[0068]

[0069]

[0070]

[0071]

[0072] Note: “+” means cleavage, “-” means no cleavage.

[0073] Example 4

[0074] Identification of bacteriophage vB_SalM-ps4 targeting host bacterial LPS receptor, the identification method is as follows:

[0075] There are many ways to identify phage host receptors, such as sequencing mutants that are resistant to phages and comparing gene mutation sites, screening transposon random mutant libraries, and constructing a knockout strain library of commonly used phage receptor genes. In this study, receptors were identified by constructing gene knockout strains of commonly used phage receptors. Enteritidis Salmonella SE006 was used as a wild-type control, and the gene-deficient strains SE006-ΔrfbP and SE006-ΔrfaL that regulate lipopolysaccharide O antigens constructed in previous studies were used as receptor identification strains (Gao et al., 2022, Fitness Trade-Offs in Phage Cocktail-ResistantSalmonella enterica Serovar Enteritidis Results in IncreasedAntibioticSusceptibility and ReducedVirulence).

[0076] The double-layer plate dot plating method was used to detect whether the phage could lyse SE006-ΔrfbP and SE006-ΔrfaL. If the phage could not lyse the gene-deficient strain, it indicated that the gene was the receptor it targeted. Figure 4 As shown, phage vB_SalM-ps4 cannot cleave rfbP and rfaL gene deletion strains that regulate O antigen, indicating that the receptor targeted by this phage is lipopolysaccharide O antigen.

[0077] Example 5

[0078] Determination of the optimal multiplicity of infection (MOI) of bacteriophage vB_SalM-ps4

[0079] The concentration of host bacteria SE006 was determined by plate spreading method. 8 PFU / mL) extract, and Salmonella enteritidis cultured to the logarithmic growth phase (10 7 CFU / mL), the bacterial solution was mixed with phage at different infection multiplicity of 100, 10, 1, 0.1, 0.01, 0.001, 0.0001 respectively, and then placed in a 37°C shaker for 4 hours, and then centrifuged at 4°C and 12000g for 1 minute. After the centrifugation, the supernatant was immediately aspirated for 10-fold gradient dilution, and the phage titer at different infection multiplicity was determined by double-layer plate method. The infection multiplicity at the highest phage titer was compared by plaque counting, which was the optimal infection multiplicity (MOI).

[0080] The results are as follows Figure 5As shown in Figure 1, when the multiplicity of infection is 1, the phage has the best effect of lysing bacteria and the highest titer. Therefore, the optimal multiplicity of infection (MOI) of the phage is 1. Figure 4 It can also be observed that the phage titer does not fluctuate much at different MOIs, indicating that the phage can be well propagated at different MOIs.

[0081] Example 6

[0082] Determination of one-step growth curve of bacteriophage vB_SalM-ps4

[0083] According to the phage vB_SalM-ps4 MOI=1, the phage vB_SalM-ps4 was mixed with the Salmonella enteritidis SE006 cultured to the logarithmic growth phase at an MOI of 1, and after oscillation and mixing, it was placed in a 37°C shaker constant temperature shaking culture for 10 minutes, and then centrifuged at 4°C and 8000g for 10 minutes, the supernatant was discarded, and the bacterial precipitate was washed with LB liquid culture medium preheated at 37°C, and the washing was repeated 3 times. After resuspending and mixing with an equal volume of preheated LB liquid culture medium, it was placed in a 37°C constant temperature shaking culture, and a sample was taken every 10 minutes. After 150 minutes, the sample was centrifuged at 10000g for 2 minutes, and the supernatant was immediately aspirated for 10-fold gradient dilution, and the phage titer at this time was determined by the double-layer plate method. The above operation was repeated three times. A one-step growth curve was drawn with the horizontal axis as the infection time and the vertical axis as the phage titer.

[0084] The results are as follows Figure 6 As shown, the incubation period of the phage is about 20 minutes when sampling is carried out every 10 minutes. After 20 minutes, the curve increases exponentially. This period is the lysis period of the phage, and the titer increases significantly. After 70 minutes, the logarithmic value of the phage titer remains basically unchanged and enters a stable period.

[0085] Example 7

[0086] Method for Determining the Temperature Stability of Bacteriophage vB_SalM-ps4

[0087] The phage vB_SalM-ps4 stock solution stored at 4°C was placed in 1.5 mL EP tubes after autoclaving, and a total of 7 temperature gradients were set. The phage was placed in a water bath at 4°C, 25°C, 37°C, 50°C, 60°C, 70°C, and 80°C for 60 min, and the phage titer at different temperatures was determined by double-layer plate method after 10-fold dilution with SM buffer. The above operation was repeated three times.

[0088] The results are as follows Figure 7As shown in the figure, the titer of the phage remained basically unchanged at a temperature below 50°C for 60 minutes, and the original activity could be maintained. After 60 minutes at 60°C, the titer of the phage could still be maintained at 1×10 7 PFU / mL. This shows that within a certain temperature range, the effect of temperature on the phage is relatively low and the thermal stability is good.

[0089] Example 8

[0090] Method for determining pH stability of bacteriophage vB_SalM-ps4

[0091] The pH value of the buffer was adjusted with HCl solution and NaOH solution, and 12 buffers with different gradients of pH (2-13) were prepared. The phage vB_SalM-ps4 stored at 4°C was placed in 1.5mL EP tubes after high-pressure sterilization. 100μL of the phage was added to the buffers with different pH values, placed in a 37°C water bath for 60min, and then diluted 10 times with SM buffer, and the phage titer at different pH values ​​was determined by double-layer plate method. The above operation was repeated three times.

[0092] The results are as follows Figure 8 As shown, the titer of the phage can still be maintained at 1×10 after being placed in a pH range of 3 to 10 for 60 minutes. 7 PFU / mL, the titer did not decrease significantly after 60 min at pH 11, and remained at 1×10 6 PFU / mL, indicating that the phage can still survive stably under different pH conditions and the phage has good pH stability.

[0093] Example 9

[0094] Method for determining the inhibitory effect of bacteriophage vB_SalM-ps4 on biofilm

[0095] Before the assay, a polyvinyl chloride 96-well plate was prepared and placed in a clean bench for ultraviolet irradiation for 20 min. The enteritidis Salmonella SE006 bacterial solution was gradiently diluted to 1×10 5CFU / mL, then 200μL of bacterial solution was added to a 96-well plate. The positive control was the bacterial solution, and the negative control was PBS buffer. The treatment groups were mixed with phages at MOIs of 1000 and 10000, respectively, and 200μL was added to a 96-well plate and placed in a 37°C constant temperature incubator for constant temperature incubation for 48 hours. After the incubation is completed, the liquid was aspirated and the wells were washed three times with PBS buffer. The residual liquid in the wells needed to be aspirated clean for the third time. Add 200μL of methanol, let it stand for 15 minutes, then aspirate the methanol and let it dry naturally. Add 200μL of 0.1% crystal violet and let it stand for 15 minutes, then rinse with running water 3 times, aspirate the liquid in the wells, let it dry naturally, add 200μL of 30% acetic acid, and use an enzyme reader to measure at 595nm (OD 595 ) to measure the absorbance.

[0096] The results are as follows Fig. 9 As shown, the phage mixed with bacterial solution can significantly inhibit the formation of biofilm of Salmonella Enteritidis SE006.

[0097] Example 10

[0098] Method for determining the effect of bacteriophage vB_SalM-ps4 on mature biofilm

[0099] Before the assay, a 96-well polyvinyl chloride plate was prepared and placed in a clean bench for UV irradiation for 20 min. Enteritidis Salmonella SE006 was gradient diluted to 1×10 5 CFU / mL, then aspirate 200μL of bacterial solution and add it to a 96-well plate, and place it in a 37℃ constant temperature incubator for constant temperature incubation for 48h. After the incubation is completed, aspirate the liquid in the wells, wash three times with PBS and dry naturally, add 200μL of phage to the wells at MOI of 1000 and 10000 respectively, and place it in a 37℃ constant temperature incubator for constant temperature incubation for 24h. After the incubation is completed, aspirate the liquid, wash the wells three times with PBS buffer, and the third time, the residual liquid in the wells needs to be aspirated. Add 200μL of methanol and let it stand for 15min, then wash out the methanol and let it dry naturally. Add 200μL of 0.1% crystal violet and let it stand for 15min, then rinse with running water 3 times, aspirate the liquid in the wells, dry naturally, add 200μL of 30% acetic acid and measure it with an enzyme marker at 595nm (OD 595 ) to measure the absorbance.

[0100] The results are as follows Fig.10 It was shown that the phage can effectively eliminate mature biofilm.

[0101] Embodiment 11

[0102] Determination of the Effective Control of Salmonella Contamination in Chicken Feed by Bacteriophage vB_SalM-ps4

[0103] Prepare three groups of granular chicken feed, each group is 10g, sterilize the chicken feed by high pressure, dry it and set aside. Dilute the host bacteria SE006 cultured overnight to a bacterial solution concentration of 10 6 CFU / mL, use a sterile sprayer to evenly spray 1 mL of diluted SE006 onto the surface of the spread feed. The control group was sprayed with an equal amount of PBS buffer, and the experimental group was sprayed with 1 mL of phage at MOI=100, MOI=1000, and MOI=10000, respectively, and then placed in a 25°C constant temperature incubator for constant temperature incubation. Samples were taken at 2h, 4h, 6h, 12h, and 24h, 1g each time, dissolved in PBS buffer, and the host bacteria SE006 content was determined after gradient dilution.

[0104] The results are as follows Fig.11 As shown, the number of bacteria in the feed can be significantly reduced at different times, indicating that the bacteriophage can effectively reduce the number of Enteritidis Salmonella in the feed, reduce the contamination of Salmonella in the feed, and block the spread of Salmonella in the feed.

[0105] Example 12

[0106] Method for determining the inhibitory effect of bacteriophage on Salmonella in chicken

[0107] The temperature was set to 25°C. The chicken was purchased from a local supermarket on the day of the test. The chicken was pre-processed. Use sterile scissors to cut the chicken into 1 cm 3 After the chicken is cut into small pieces, 75% alcohol by volume is evenly applied on the surface of the chicken and placed in a clean bench under ultraviolet light for 30 minutes to prepare a sterile chicken sample. 5 CFU / mL of host bacteria SE006 was evenly sprayed on the surface of sterile chicken samples to obtain chicken samples artificially infected with SE006. To ensure that the host bacteria SE006 on the surface of chicken can be fully adsorbed, the chicken samples were placed in a clean bench to air dry. The phage was evenly sprayed on the treated chicken surface at a ratio of MOI=1000 and MOI=10000. The control group was the same volume of PBS buffer. The two groups of samples at different temperatures were placed in a 4℃ refrigerator and a 25℃ constant temperature incubator, respectively. Samples were taken at 0, 2, 4, 6, 12, and 24 hours, respectively, and placed in PBS buffer. After mixing, centrifuged at 8000g for 5 minutes, the supernatant was discarded, and the precipitate was diluted 10 times. The plate coating method was used to count and calculate the antibacterial effect of the phage. The bactericidal efficiency calculation formula is: (the number of bacteria in the control group-the number of bacteria in the experimental group) ÷ the number of bacteria in the control group × 100%, formula II.

[0108] The results are as follows Fig.12As shown in the figure, after the chicken samples were treated with phages at MOI=1000 at 25°C for 6 hours, the bacterial count was reduced by 2.41lg (CFU / mL) compared with the control group, and the bactericidal efficiency was 99.5%. After the chicken samples were treated with phages at MOI=10000 at 25°C for 6 hours, the bacterial count was reduced by 2.30lg (CFU / mL) compared with the control group, and the bactericidal efficiency reached 99.6%, and the inhibition was more obvious at 24 hours.

[0109] The bacteriophage inhibition experiment on chicken described in Example 10 proves that the bacteriophage has a significant inhibitory effect on Salmonella enteritidis in food.

[0110] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A Salmonella phage vB_SalM-ps4, wherein the deposit number of the Salmonella phage vB_SalM-ps4 is CCTCC NO: M 20241333.

2. Use of the Salmonella phage vB_SalM-ps4 according to claim 1 in one or both of the following: 1) Preparation of preparations for inhibiting and / or eliminating Salmonella; 2) Preparation of preparations for inhibiting and / or eliminating Escherichia coli.

3. The use according to claim 2, characterized in that: The preparation in 1) includes a preparation that targets Salmonella polysaccharides and / or removes Salmonella biofilm.

4. The use according to claim 2, characterized in that: The Escherichia coli includes Escherichia coli serotype O157.

5. The use according to claim 2 or 3, characterized in that: The salmonella includes one or more of Salmonella Enteritidis, Salmonella Pullorum, Salmonella Stanley, Salmonella Chester, Salmonella Infantis and Salmonella Typhimurium.

6. The use according to claim 2, characterized in that: The preparation includes one or more of the following four items: 1) Drugs for preventing and / or treating diseases caused by Escherichia coli infection; 2) Drugs for preventing and / or treating diseases caused by Salmonella infection; 3) Food antibacterial agent; 4) Disinfectant.

7. The use according to claim 6, characterized in that: The food comprises food of animal origin.

8. A preparation, characterized in that The preparation comprises auxiliary materials and the Salmonella phage vB_SalM-ps4 according to claim 1.

9. The preparation according to claim 8, characterized in that The auxiliary materials include feed; The content of Salmonella phage vB_SalM-ps4 in the preparation is 10 6 PFU / mL~10 9 PFU / mL.

10. Use of the Salmonella phage vB_SalM-ps4 according to claim 1 or the preparation according to claim 8 or 9 in livestock and poultry breeding and / or livestock and poultry food processing.

Citation Information

Patent Citations

  • Salmonella phage LPSE34 and application thereof in food

    CN108588037A

  • Novel bacteriophage and antibacterial composition comprising the same

    US20110052542A1